ACRV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	276 138
Average Volume	761 304
Market Cap	261.18M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.950 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.09
ATR14	$0.0520 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Miller Mary	Sell	558	Common Stock
2024-04-11	Ra Capital Management, L.p.	Buy	3 530 000	Common Stock
2024-04-11	Perceptive Advisors Llc	Buy	2 353 000	Common Stock
2024-03-04	Palani Santhosh	Buy	32 500	Stock Option (Right to Buy)
2024-03-04	Palani Santhosh	Buy	0

INSIDER POWER
23.44
Last 56 transactions
Buy: 13 025 326 \| Sell: 16 556 327

Volume Correlation

Long: -0.23 (neutral)

Short: -0.76 (moderate negative)

Signal:(54.327) Neutral

Acrivon Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acrivon Therapeutics, Correlation - Currency/Commodity

-0.34
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.45
( neutral )

-0.15
( neutral )

0.52
( weak )

Acrivon Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-536 000 (0.00 %)
EPS:	$-2.74

FY	2023
Revenue:	$0
Gross Profit:	$-536 000 (0.00 %)
EPS:	$-2.74

FY	2022
Revenue:	$0
Gross Profit:	$-1.10M (0.00 %)
EPS:	$-1.350

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.260

Financial Reports:

No articles found.

Acrivon Therapeutics,

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.